In the present work we have investigated on the mechanism through which stimulation of hERG1 channel leads to a rapid down-regulation of cyclin E2, assessed the impact of this inhibition in tumor cells arising from a variety of breast cancer subtypes, and considered the potential of hERG1 activators in treating breast cancers that have become resistant to therapy. This evidence concerns the gene KCNH2 and breast carcinoma.